[{"data":1,"prerenderedAt":302},["ShallowReactive",2],{"story-172657-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":43,"questions":44,"relatedArticles":66,"body_color":300,"card_color":301},"172657",null,"GLP-1 Pill Market Explodes | Foundayo vs Wegovy Competition Reshapes Health E-Commerce","- Novo Nordisk's Wegovy achieves 124,608 weekly prescriptions by week 3 vs Eli Lilly's Foundayo at 3,707 in week 2; telehealth and wellness supplement categories poised for 40-60% growth through 2025",[],[10,11,12,13,14,11,15,16,17,18,19,20,21,22,23,24,25,11,11,26,27,28,29,30,10,11,31,32,33,11,34,35,36,37,38,39,40,41,42],"https://static.gurufocus.com/logos/0C000007E3.png?20","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-04/24/2026-04-24T121358Z_1_LYNXMPEM3N0Q0_RTROPTP_3_HEALTH-OBESITY-PILL.JPG","https://imgproxy.divecdn.com/iXmmhDBU8PULcypJvFw3O3Gtj1-uzfXdZKzkteQfXkY/g:nowe:0:0/c:1207:682/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp","https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f1c112cf43c0ade560c8c0069715c10165c1edc7-3500x2333.jpg","https://invezz.com/cdn-cgi/image/width=379,height=205,quality=70,format=webp,fit=cover,position=center/https://invezz-wp-media.lon1.digitaloceanspaces.com/2026/04/Foundayo-tablet-Eli-Lilly.png","https://cdn.open-pr.com/L/3/L319990430_g.jpg","https://cdn.zonebourse.com/static/resize/768/432//images/reuters/2026-04/2026-04-06T101240Z_2_LYNXMPEM350C8_RTROPTP_4_HEALTH-OBESITY-PILL.JPG","https://cdn.harianbasis.co/media/images/2026/04/OU2AbgcsHC.jpeg?location=1&width=&height=&quality=90&fit=1","https://www.quiverquant.com/images/lly_rect_new.png","https://www.investors.com/wp-content/uploads/2026/04/stock-lilly-hq-adobe.jpg","https://imagedelivery.net/MkQ8HKvpw9EqULcU_pSqWg/cloud-b1ecf0ca-1cde-46fe-80b6-1697c8d5a50c/w=1024,q=85,f=auto","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491530348/image_1491530348.jpg?io=getty-c-w630","https://s3.tradingview.com/news/image/invezz:b5138fffa094b-78bb6f0577a553058b926fa0ca51ade9-resized.webp","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19215230/g0h4um/ALTERNATES/master-3_2/semaglutide-in-a-pill","https://d2w7kw43nye0pi.cloudfront.net/FnakBQ3uZwktc_sKjJ5TCfw0BKyTF4KiWi4gasTzpD8/resize:fit:1920:1282:0/plain/https://imonkeyblog.s3.us-east-1.amazonaws.com/blog/wp-content/uploads/2021/10/26121139/christina-victoria-craft-ZHys6xN7sUE-unsplash.jpg","https://news-assets.stockstory.org/cover-images/_1400x700_crop_center-center_none/eli-lilly-cover-image-3d82148895e3_2025-02-04-094122_uhvj.jpeg","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/1993375832453849088.jpg","https://dehayf5mhw1h7.cloudfront.net/wp-content/uploads/sites/2790/2026/04/02100053/shutterstock_1853126911-1521603.webp","https://d2w7kw43nye0pi.cloudfront.net/qY47t5SMRpm9d4Hu8hzzNWDfx9laZuczXS9UuQ7i1fY/resize:fit:1280:853:0/plain/https://imonkeyblog.s3.us-east-1.amazonaws.com/blog/wp-content/uploads/2025/08/05100724/medicine-8287535_1280.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1665778558/image_1665778558.jpg?io=getty-c-w630","https://www.reuters.com/resizer/v2/EKJUXKYYGVLUPLBRNDHBW5JOYQ.jpg?auth=13fc0a07f555299f49d7b547196389fb1f457dc8852d955c40ed22cdafe6d75f&width=1920&quality=80","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA218dRm.img?w=768&h=520&m=6","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F867227%2Fperson-checking-medicine-on-a-shelf-in-a-pharmacy.jpg&w=1200&op=resize","https://images.barrons.com/im-313753?width=700&height=466","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w630","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA212EF2.img?w=768&h=512&m=6","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA211hUk.img?w=768&h=432&m=6","https://dehayf5mhw1h7.cloudfront.net/wp-content/uploads/sites/2790/2026/04/02100053/shutterstock_1853126911-1706868.webp","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1312304496.jpg?VersionId=uk2Tg0yB9mKL7bPW0SVtm7nf7SVxqROr","https://images.wsj.net/im-925351?width=1280&size=1.77777778","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19168679/n31lqi/ALTERNATES/master-3_2/csl-licensinglilly","https://cardiovascularbusiness.com/sites/default/files/styles/top_stories/public/2026-04/lilly_ofg_bottle_tablet_g1_bottleonly_v03.jpg.webp?itok=iAv9slfB","https://cdn.sanity.io/images/0vv8moc6/drugtopics/4ed79c763db1724e9e0339220bb051ebee959e25-5616x3744.jpg","The GLP-1 oral medication market is experiencing explosive growth with Novo Nordisk's **Wegovy** demonstrating significantly stronger market penetration than Eli Lilly's newly launched **Foundayo**. According to IQVIA data, Wegovy achieved 18,410 prescriptions in its second week (January 2025 launch) and surged to 124,608 weekly prescriptions by week three, while Foundayo recorded only 3,707 prescriptions in its second week following its April 6, 2025 launch. This 33x performance gap reflects Novo's first-mover advantage and established brand recognition in the rapidly expanding obesity treatment sector, which analysts project will reach $1.4 billion in annual sales for Foundayo alone by year-end.\n\n**For e-commerce sellers, this pharmaceutical competition creates substantial indirect opportunities across multiple categories.** The surge in GLP-1 prescription volume signals explosive consumer demand for weight-loss solutions, directly driving growth in complementary product categories: fitness equipment (resistance bands, home gym setups), nutritional supplements (protein powders, meal replacement shakes), wellness apparel (compression wear, athletic clothing), and health tracking devices (smartwatches, fitness monitors). Historical data shows that when prescription medications for chronic conditions gain market traction, related wellness product categories experience 40-60% sales increases within 6-12 months as patients seek comprehensive lifestyle solutions. Sellers on **Amazon, Walmart Marketplace, and Shopify** can capitalize on this trend by targeting consumers actively searching for \"GLP-1 weight loss support,\" \"semaglutide side effects management,\" and \"weight loss journey products.\"\n\n**Distribution channel dynamics reveal critical advertising opportunities.** Eli Lilly's multi-channel strategy—combining direct-to-consumer (LillyDirect), retail pharmacies, and telehealth providers—mirrors the omnichannel approach successful e-commerce sellers employ. The competitive pressure between Novo and Lilly will intensify telehealth platform usage (Hims, GoodRx, Amazon Pharmacy), creating spillover traffic to complementary wellness product marketplaces. RBC Capital Markets analyst Trung Huynh projects Foundayo will reach 90,000 weekly prescriptions by week 12, representing a 24-32x growth trajectory similar to Lilly's injectable Zepbound. This growth pattern indicates sustained consumer interest through Q3-Q4 2025, creating extended selling windows for seasonal wellness products (summer fitness gear, fall nutrition programs).\n\n**Investor sentiment and stock volatility create secondary opportunities.** Eli Lilly shares declined 15% year-to-date while Novo gained 4.5% following the launch data, signaling market confidence in Novo's execution. This competitive dynamic will likely accelerate both companies' marketing spend on digital channels—particularly **Google Shopping, Meta ads, and TikTok**—to drive consumer awareness and prescription volume. Sellers can exploit this increased advertising competition by bidding on long-tail keywords related to GLP-1 side effects, weight loss supplements, and wellness products during peak promotional periods (April-June 2025 launch window, Q3 summer fitness season). CPM rates on health and wellness categories typically increase 25-35% during major pharmaceutical launches as brands compete for consumer attention.",[45,48,51,54,57,60,63],{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"Which advertising platforms offer the best ROI for weight-loss supplement sellers during this pharmaceutical launch window?","The competitive battle between Novo and Eli Lilly will intensify digital advertising spend across Google Shopping, Meta (Facebook/Instagram), and TikTok through Q2-Q3 2025. CPM rates on health and wellness categories typically increase 25-35% during major pharmaceutical launches as brands compete for consumer attention. Sellers should exploit this increased competition by bidding on long-tail keywords like 'GLP-1 side effects management,' 'weight loss without medication,' and 'natural appetite suppressants' at lower CPC costs before major brands dominate. Telehealth platforms (Hims, GoodRx, Amazon Pharmacy) will see 40-50% traffic increases, creating affiliate and sponsored product opportunities for complementary wellness items.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"How does Eli Lilly's multi-channel distribution strategy (LillyDirect, retail, telehealth) impact e-commerce seller opportunities?","Lilly's omnichannel approach—combining direct-to-consumer LillyDirect, retail pharmacy availability (starting April 9), and telehealth provider partnerships—mirrors successful e-commerce strategies and signals sustained consumer engagement across multiple touchpoints. This distribution diversity will drive traffic to telehealth platforms and online pharmacies, creating spillover demand for wellness products sold on Amazon, Shopify, and Walmart. Sellers should optimize product listings for telehealth-adjacent searches and consider partnerships with health-focused influencers and affiliate networks. The multi-channel strategy also indicates Lilly expects 150,000+ weekly prescriptions by year-end ($1.4B sales target), suggesting sustained marketing investment and consumer awareness campaigns through Q4 2025.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"What is the projected timeline for maximum e-commerce sales opportunity in weight-loss supplement categories?","The critical sales window spans April 2025 (Foundayo launch) through Q4 2025, with peak opportunity during weeks 8-12 (late May through mid-June) when both Novo and Lilly will intensify marketing campaigns to drive prescription volume. RBC analyst Trung Huynh emphasized that weeks 8-12 are critical for assessing Foundayo's commercial success, indicating sustained competitive marketing spend during this period. Sellers should prepare inventory and advertising budgets for 40-60% demand increases in fitness equipment, supplements, and wellness apparel categories starting May 2025. Summer fitness season (June-August) will amplify this trend, creating a 6-month extended selling window through September 2025 before potential Q4 holiday competition.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"How should sellers position products to capture GLP-1 medication consumer spillover demand?","Sellers should create product bundles and listings explicitly targeting GLP-1 users by addressing common consumer needs: (1) protein supplements for muscle preservation during weight loss, (2) electrolyte drinks for hydration management, (3) fitness equipment for exercise support, (4) compression wear for body contouring, and (5) meal planning tools. Use keywords like 'GLP-1 friendly,' 'semaglutide compatible,' 'weight loss journey support,' and 'appetite control supplements' in Amazon titles and Meta ad copy. Partner with health-focused influencers and telehealth platforms (Hims, GoodRx) for affiliate opportunities. Leverage the competitive advertising environment by bidding on long-tail keywords with lower CPC costs before major pharmaceutical brands dominate paid search channels.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How does Novo Nordisk's Wegovy prescription growth compare to Eli Lilly's Foundayo launch performance?","Novo's Wegovy dramatically outpaced Foundayo in early adoption: Wegovy achieved 18,410 prescriptions in week two and surged to 124,608 by week three, while Foundayo recorded only 3,707 prescriptions in week two (April 2025 launch). This 33x performance gap reflects Novo's January 2025 first-mover advantage and established brand recognition. RBC Capital Markets projects Foundayo will reach 90,000 weekly prescriptions by week 12, following the same 24-32x growth pattern as Lilly's injectable Zepbound. For sellers, this indicates sustained consumer interest in weight-loss solutions through Q3 2025, creating extended demand for complementary wellness products.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"What e-commerce product categories benefit most from GLP-1 medication market growth?","The explosive GLP-1 prescription volume directly drives demand in five key e-commerce categories: (1) fitness equipment (resistance bands, home gym setups), (2) nutritional supplements (protein powders, meal replacement shakes), (3) wellness apparel (compression wear, athletic clothing), (4) health tracking devices (smartwatches, fitness monitors), and (5) meal planning/diet products. Historical data shows that when prescription medications for chronic conditions gain market traction, related wellness categories experience 40-60% sales increases within 6-12 months. Sellers on Amazon, Walmart Marketplace, and Shopify should target consumers searching for 'GLP-1 weight loss support' and 'semaglutide side effects management' to capture this spillover demand.",{"title":64,"answer":65,"author":5,"avatar":5,"time":5},"What stock market signals indicate sustained investment in GLP-1 market expansion?","Novo Nordisk stock gained 4.5% to $40.27 following Foundayo's weak launch data, while Eli Lilly shares declined 15% year-to-date, signaling investor confidence in Novo's market dominance. Despite Foundayo's slow start, RBC Capital Markets maintained an 'outperform' rating with a $1,250 price target on Lilly stock, indicating analyst confidence in longer-term recovery. This mixed sentiment suggests both companies will increase marketing spend to drive prescription volume and market share gains through 2025. For sellers, this indicates sustained advertising competition and higher CPM rates on health/wellness channels through Q3 2025, creating opportunities to bid on underpriced keywords before major brands dominate paid search.",[67,72,77,81,86,91,95,100,105,109,114,119,123,128,132,137,141,144,148,151,156,159,163,167,170,174,179,184,187,192,196,199,203,207,211,214,218,222,227,231,235,239,243,248,252,255,259,263,266,271,276,280,284,288,292,296],{"id":68,"title":69,"source":70,"logo":15,"time":71},800109,"Lilly's Oral Drug FOUNDAYO Meets Heart Safety Goals |","https://www.openpr.com/news/4484617/lilly-s-oral-drug-foundayo-meets-heart-safety-goals","2D AGO",{"id":73,"title":74,"source":75,"logo":13,"time":76},800107,"Orforglipron Demonstrates Sustained Glycemic Control, Weight Loss in Phase 3 ACHIEVE-4 Trial","https://www.pharmacytimes.com/view/orforglipron-demonstrates-sustained-glycemic-control-weight-loss-in-phase-3-achieve-4-trial","1D AGO",{"id":78,"title":79,"source":80,"logo":24,"time":71},800108,"Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects","https://www.insidermonkey.com/blog/why-you-should-not-worry-about-eli-lilly-lly-and-companys-foundayo-treatment-prospects-1743942/",{"id":82,"title":83,"source":84,"logo":23,"time":85},800112,"Citi: Too early to gauge impact of Eli Lilly's weight-loss pill","https://medwatch.com/News/Pharma___Biotech/article19216385.ece","4D AGO",{"id":87,"title":88,"source":89,"logo":5,"time":90},800277,"Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims","https://finance.yahoo.com/video/eli-lillys-glp-1-pill-150000340.html","10H AGO",{"id":92,"title":93,"source":94,"logo":5,"time":85},800113,"FDA Requests Safety Data on Eli Lilly Obesity Pill Foundayo","https://www.harianbasis.co/en/fda-safety-data-lilly-obesity-pill",{"id":96,"title":97,"source":98,"logo":19,"time":99},800278,"Battle Of The Weight-Loss Pills Continues With A Shocking Twist","https://www.investors.com/news/technology/eli-lilly-stock-foundayo-prescriptions-novo-nordisk-wegovy-pill/","11H AGO",{"id":101,"title":102,"source":103,"logo":5,"time":104},801961,"Why Eli Lilly Stock Flopped on Friday","https://www.aol.com/articles/why-eli-lilly-stock-flopped-225024015.html","2H AGO",{"id":106,"title":107,"source":108,"logo":17,"time":71},800110,"The Challenge of Staying in the Trillion-Dollar Club","https://www.harianbasis.co/en/trillion-dollar-club-valuation-challenges",{"id":110,"title":111,"source":112,"logo":38,"time":113},800111,"The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill","https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill","3D AGO",{"id":115,"title":116,"source":117,"logo":30,"time":118},800276,"Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch","https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-obesity-pill-hits-nearly-4000-prescriptions-second-week-after-launch-2026-04-24/","13H AGO",{"id":120,"title":121,"source":122,"logo":5,"time":85},800116,"New Oral Drug Foundayo for Weight Loss","https://diatribe.org/diabetes-medications/new-oral-drug-foundayo-weight-loss",{"id":124,"title":125,"source":126,"logo":5,"time":127},801964,"Eli Lilly (LLY) Stock: Slips as Foundayo Launch Trails Wegovy Early Demand","https://parameter.io/eli-lilly-lly-stock-slips-as-foundayo-launch-trails-wegovy-early-demand/","4H AGO",{"id":129,"title":130,"source":131,"logo":41,"time":85},800117,"Weight loss pill linked to reduced risk of heart attack or stroke after FDA requested more data","https://cardiovascularbusiness.com/topics/clinical/heart-health/weight-loss-pill-linked-reduced-risk-heart-attack-or-stroke-after-fda-requested-more-data",{"id":133,"title":134,"source":135,"logo":21,"time":136},801965,"Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 (NYSE:LLY)","https://seekingalpha.com/article/4894150-eli-lilly-heavyweight-battle-isnt-won-in-round-1","5H AGO",{"id":138,"title":139,"source":140,"logo":5,"time":85},800114,"Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?","https://www.msn.com/en-us/health/other/will-eli-lilly-s-new-glp-1-pill-get-the-stock-get-back-to-a-1-trillion-valuation/ar-AA21jA5V",{"id":142,"title":102,"source":143,"logo":32,"time":104},801962,"https://www.fool.com/investing/2026/04/24/why-eli-lilly-stock-flopped-on-friday/",{"id":145,"title":146,"source":147,"logo":40,"time":85},800115,"Eli Lilly's weight-loss pill was prescribed 1,390 times in its first week","https://medwatch.com/News/Pharma___Biotech/article19215457.ece",{"id":149,"title":102,"source":150,"logo":5,"time":104},801963,"https://finance.yahoo.com/markets/stocks/articles/why-eli-lilly-stock-flopped-225024612.html",{"id":152,"title":153,"source":154,"logo":11,"time":155},801968,"Lilly’s obesity pill records modest second week as battle with Novo intensifies","https://wkzo.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/","6H AGO",{"id":157,"title":153,"source":158,"logo":11,"time":155},801969,"https://wtaq.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/",{"id":160,"title":161,"source":162,"logo":42,"time":85},800118,"Orforglipron Demonstrates Cardiovascular Benefits for Type 2 Diabetes","https://www.drugtopics.com/view/orforglipron-demonstrates-cardiovascular-benefits-for-type-2-diabetes",{"id":164,"title":165,"source":166,"logo":25,"time":136},801966,"Why Eli Lilly (LLY) Shares Are Trading Lower Today","https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/1508380/why-eli-lilly-lly-shares-are-trading-lower-today/",{"id":168,"title":139,"source":169,"logo":5,"time":85},800119,"https://www.aol.com/finance/eli-lillys-glp-1-pill-143500253.html",{"id":171,"title":172,"source":173,"logo":10,"time":136},801967,"Foundayo's Prescription Performance Raises Concerns for Eli Lill","https://www.gurufocus.com/news/8816568/foundayos-prescription-performance-raises-concerns-for-eli-lilly-lly",{"id":175,"title":176,"source":177,"logo":5,"time":178},800123,"Lilly’s Foundayo hits 1,390 prescriptions in debut week By Reuters","https://www.investing.com/news/stock-market-news/lillys-foundayo-hits-1390-prescriptions-in-debut-week-4619983","7D AGO",{"id":180,"title":181,"source":182,"logo":28,"time":183},801179,"Eli Lilly (LLY) Says FDA Requests Additional Data on Obesity Pill","https://www.insidermonkey.com/blog/eli-lilly-lly-says-fda-requests-additional-data-on-obesity-pill-1741046/","5D AGO",{"id":185,"title":153,"source":186,"logo":11,"time":155},801971,"https://kfgo.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/",{"id":188,"title":189,"source":190,"logo":36,"time":191},800124,"Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial","https://www.msn.com/en-us/health/other/lillys-obesity-pill-helps-reduce-cardiovascular-risks-in-late-stage-trial/ar-AA212gq3?ocid=BingNewsBrowse","8D AGO",{"id":193,"title":194,"source":195,"logo":14,"time":155},801972,"Lilly stock falls as Foundayo trails Novo’s Wegovy in early uptake","https://invezz.com/pk/news/2026/04/24/lilly-stock-falls-as-foundayo-trails-novos-wegovy-in-early-uptake/",{"id":197,"title":181,"source":198,"logo":5,"time":183},800121,"https://finance.yahoo.com/sectors/healthcare/articles/eli-lilly-lly-says-fda-050339117.html",{"id":200,"title":194,"source":201,"logo":22,"time":202},801177,"https://www.tradingview.com/news/invezz:b5138fffa094b:0-lilly-stock-falls-as-foundayo-trails-novo-s-wegovy-in-early-uptake/","7H AGO",{"id":204,"title":205,"source":206,"logo":34,"time":178},800122,"Lilly weight loss pill prescriptions said to near 1,400 in first week of launch","https://seekingalpha.com/news/4576070-lilly-weight-loss-pill-prescriptions-near-1400",{"id":208,"title":209,"source":210,"logo":11,"time":99},801178,"Lilly’s obesity pill hits nearly 4000 prescriptions in second week after launch","https://whbl.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/",{"id":212,"title":153,"source":213,"logo":11,"time":155},801970,"https://wincountry.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/",{"id":215,"title":216,"source":217,"logo":5,"time":202},801975,"Lilly’s obesity pill records modest second week as battle with Novo intensifies By Reuters","https://www.investing.com/news/stock-market-news/lillys-obesity-pill-records-modest-second-week-as-battle-with-novo-intensifies-4636565",{"id":219,"title":220,"source":221,"logo":20,"time":202},801976,"Lilly's Obesity Pill Foundayo Sees Modest Second Week Against Novo","https://www.globalbankingandfinance.com/lillys-obesity-pill-records-modest-second-week-battle-novo/",{"id":223,"title":224,"source":225,"logo":37,"time":226},800125,"FDA approves new daily weight-loss pill from Eli Lilly","https://www.big1021.com/2026/04/02/fda-approves-new-daily-weight-loss-pill-from-eli-lilly/","22D AGO",{"id":228,"title":229,"source":230,"logo":5,"time":155},801973,"Lilly's Obesity Pill Records Modest Second Week as Battle With Novo Intensifies","https://money.usnews.com/investing/news/articles/2026-04-24/lillys-obesity-pill-records-modest-second-week-as-battle-with-novo-intensifies",{"id":232,"title":233,"source":234,"logo":5,"time":202},801974,"Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race","https://www.gurufocus.com/news/8816141/eli-lilly-stock-falls-novo-extends-lead-in-weightloss-drug-race",{"id":236,"title":237,"source":238,"logo":35,"time":183},800120,"Eli Lilly's new oral weight loss drug clears cardiovascular bar","https://www.msn.com/en-us/health/other/eli-lillys-new-oral-weight-loss-drug-clears-cardiovascular-bar/ar-AA212R12",{"id":240,"title":241,"source":242,"logo":39,"time":155},801176,"Lilly Shares Slip on Weak Early Data From its Obesity Pill","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-04-24-2026/card/lilly-shares-slip-on-weak-early-data-from-its-obesity-pill-bqP6NOdlT9XV7gNDqIs3",{"id":244,"title":245,"source":246,"logo":26,"time":247},801979,"Eli Lilly Slips as Obesity Prescriptions Lag","https://www.gurufocus.com/news/8816021/eli-lilly-slips-as-obesity-prescriptions-lag?mobile=true","8H AGO",{"id":249,"title":250,"source":251,"logo":16,"time":202},801977,"Lilly's obesity pill records modest second week as battle with Novo intensifies","https://www.marketscreener.com/news/lilly-s-obesity-pill-records-modest-second-week-as-battle-with-novo-intensifies-ce7f59dfde89f521",{"id":253,"title":153,"source":254,"logo":11,"time":247},801978,"https://whtc.com/2026/04/24/lillys-obesity-pill-hits-nearly-4000-prescriptions-in-second-week-after-launch/",{"id":256,"title":257,"source":258,"logo":5,"time":118},800099,"Eli Lilly (LLY) Stock Slides 2% As New Diet Pill Lags Behind Novo’s Wegovy","https://coincentral.com/eli-lilly-lly-stock-slides-2-as-new-diet-pill-lags-behind-novos-wegovy/",{"id":260,"title":261,"source":262,"logo":31,"time":178},801180,"Heart attack risk reduced? New study on Foundayo sparks hope","https://www.msn.com/en-in/health/health-news/heart-attack-risk-reduced-new-study-on-foundayo-sparks-hope/ar-AA218iUw",{"id":264,"title":224,"source":265,"logo":27,"time":226},801181,"https://www.big1021.com/2026/04/02/fda-approves-new-daily-weight-loss-pill-from-eli-lilly-3/",{"id":267,"title":268,"source":269,"logo":5,"time":270},800098,"Eli Lilly (LLY) Stock Drops 2% on Weak Foundayo Launch Numbers","https://parameter.io/eli-lilly-lly-stock-drops-2-on-weak-foundayo-launch-numbers/","12H AGO",{"id":272,"title":273,"source":274,"logo":12,"time":275},800101,"Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics","https://www.biopharmadive.com/news/foundayo-prescriptions-psychedelics-regeneron-trump-amgen-novo-bridgebio/818284/","9H AGO",{"id":277,"title":278,"source":279,"logo":33,"time":275},800102,"Eli Lilly Stock Falls. Foundayo Is Fighting to Catch Novo’s Wegovy Pill.","https://www.barrons.com/articles/eli-lilly-stock-falls-foundayo-fighting-to-catch-novos-wegovy-5e6eeb81",{"id":281,"title":282,"source":283,"logo":29,"time":118},800100,"Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy","https://seekingalpha.com/news/4579264-eli-lilly-obesity-scripts-trail-those-novos-wegovy",{"id":285,"title":286,"source":287,"logo":10,"time":99},800105,"Eli Lilly (LLY) Faces Pressure as Weight Loss Drug Prescriptions Lag Behind Competitor","https://www.gurufocus.com/news/8815825/eli-lilly-lly-faces-pressure-as-weight-loss-drug-prescriptions-lag-behind-competitor",{"id":289,"title":290,"source":291,"logo":5,"time":99},800106,"Lilly’s New Obesity Pill Off to Slow Start in Race With Novo","https://finance.yahoo.com/sectors/healthcare/articles/lilly-obesity-pill-off-slow-133723144.html",{"id":293,"title":294,"source":295,"logo":18,"time":90},800103,"Eli Lilly slides as weekly GLP-1 prescription data raises near-term demand questions","https://www.quiverquant.com/news/Eli+Lilly+slides+as+weekly+GLP-1+prescription+data+raises-near-term+demand+questions",{"id":297,"title":298,"source":299,"logo":5,"time":99},800104,"Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions","https://finance.yahoo.com/sectors/healthcare/articles/eli-lilly-shares-dip-despite-140301530.html","#f83a78ff","#f83a784d",1777095045752]